Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH “Least Burdensome” Guidance Promotes FDA Staff, Panelist Training

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to conduct training sessions to ensure that CDRH staffers and device advisory panel members apply "least burdensome" principles to their work, according to a final guidance posted on the CDRH website Sept. 30 and published in the Federal Register Oct. 4

You may also be interested in...



User Fees Would Bring Implementation Challenges Along With Resource Boon

A medical device user fee program would be resource-intensive initially, according to an FDA Center for Devices & Radiological Health topsider, given the complexities associated with set-up

User Fees Would Bring Implementation Challenges Along With Resource Boon

A medical device user fee program would be resource-intensive initially, according to an FDA Center for Devices & Radiological Health topsider, given the complexities associated with set-up

Least Burdensome Draft Guidance Defers Issue Of Claims Substantiation

Claims substantiation will be addressed in a future guidance separate from the Center for Devices and Radiological Health's draft guidance outlining "least burdensome" concepts and principles.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel